再鼎医药宣布，其创新药物Tivdak®（注射用替索妥玛维度汀）已获得中国国家药品监督管理局的上市批准。该药物适用于治疗既往接受过系统治疗后出现疾病进展的复发或转移性宫颈癌成年患者。
这一批准标志着再鼎医药在肿瘤治疗领域取得了重要进展，为国内面临治疗困境的宫颈癌患者提供了新的治疗选择。Tivdak®是一种靶向组织因子（TF）的抗体药物偶联物（ADC），旨在精准递送细胞毒性药物至癌细胞，在关键临床研究中展现了具有前景的疗效和安全性数据。
获得监管批准是药物商业化进程中的关键一步。预计此次获批将有望拓展再鼎医药的产品组合，并对其未来的营收增长产生积极影响。公司表示将继续致力于将创新疗法引入中国市场，以满足未满足的医疗需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.